Disease · MONDO_0012511

preterm premature rupture of the membranes

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. preterm premature rupture of the membranes. Diseases, record MONDO_0012511. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0012511

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: preterm premature rupture of the membranes; Open Targets
Open Targets ID: MONDO_0012511; Open Targets
Other names: PPROM, preterm premature rupture of the membranes, susceptibility to; Open Targets
Disease Ontology: DOID:0111144; Disease Ontology
MeSH: C563032; MeSH
NCI Thesaurus: C92862; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 16 of its 22 drugs, from ClinicalTrials.gov; Open Targets

Drugs22

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
AZITHROMYCIN	CHEMBL529	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
ERYTHROMYCIN	CHEMBL532	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
CLARITHROMYCIN	CHEMBL1741	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
AMOXICILLIN	CHEMBL1082	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
BETAMETHASONE	CHEMBL632	Small molecule	Phase 3	ClinicalTrials.gov	2	2	1	Drugs and targets
CEFAZOLIN	CHEMBL1435	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ALPHA-TOCOPHEROL	CHEMBL47	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ASCORBIC ACID	CHEMBL196	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
BETAMETHASONE SODIUM PHOSPHATE	CHEMBL1200762	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets

1 to 10 of 22

See all 22 drugs

Targets8

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	8	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
CACNA1C	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Phase 3	https://conductscience.org/library/genes/775	Drugs and targets
CACNA1D	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Phase 3	https://conductscience.org/library/genes/776	Drugs and targets
CACNA1F	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Phase 3	https://conductscience.org/library/genes/778	Drugs and targets
CACNA1S	Voltage-gated L-type calcium channel	1	Voltage-gated L-type calcium channel blocker	Phase 3	https://conductscience.org/library/genes/779	Drugs and targets
PGR	Progesterone receptor	1	Progesterone receptor agonist	Phase 2	https://conductscience.org/library/genes/5241	Drugs and targets
PTGS1	Cyclooxygenase	1	Cyclooxygenase inhibitor	Phase 2	https://conductscience.org/library/genes/5742	Drugs and targets
PTGS2	Cyclooxygenase	1	Cyclooxygenase inhibitor	Phase 2	https://conductscience.org/library/genes/5743	Drugs and targets

Trials15

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01050647	Progesterone for the Management of Preterm, Premature Rupture of the Membranes: A Randomized Controlled Trial.	Phase 1/2	21	2018-04-17	Pregnancy Complications	HYDROXYPROGESTERONE CAPROATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT03060473	Treatment of ppROM With Erythromycin vs. Azithromycin Trial	Phase 3	21	2024-06-25	Preterm Premature Rupture of Membranes (PPROM)	AZITHROMYCIN, ERYTHROMYCIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT03976063	Tocolysis in the Management of Preterm Premature Rupture of Membranes Before 34 Weeks of Gestation	Phase 3	857		Preterm Premature Rupture of Membrane	NIFEDIPINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT07394725	Unlocking New Avenues: Azithromycin Vs Erythromycin in Pre-term, Pre-mature Rupture of Membrane Management	Phase 1	250		Pre-term Premature Rupture of Membranes	AZITHROMYCIN, ERYTHROMYCIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT01266928	Does Vitamins C and E Supplementation of After Preterm Rupture of Membranes Prolong the Duration of Latency? A Prospective Randomized Controlled Study	Phase 3	244		Preterm Premature Rupture of Membranes	ALPHA-TOCOPHEROL, ASCORBIC ACID	Open Targets' reading of its record	ClinicalTrials.gov
NCT05328817	Azithromycin Versus Erythromycin For Preterm Prelabor Rupture of Membranes	Not applicable	240		Preterm Premature Rupture of Membrane	AZITHROMYCIN, ERYTHROMYCIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT01503606	Duration of Antibiotics Treatment With Cefazolin and Clarithromycin in Women With Preterm Premature Rupture of Membrane	Phase 3	151		Preterm Premature Rupture of Membrane	CEFAZOLIN, CLARITHROMYCIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT05134688	Magnesium Sulphate in Premature Rupture of Membranes		124		Premature Rupture of Membrane	MAGNESIUM SULFATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00466128	Indomethacin Versus Placebo in Women With Preterm Premature Rupture of Membranes (PPROM)	Phase 2	116		Preterm Premature Rupture of Membranes	INDOMETHACIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT01401179	Antibiotics Study in Preterm Premature Rupture of the Membranes	Phase 3	101		Preterm Premature Rupture of the Membranes	CEFAZOLIN, CLARITHROMYCIN, ERYTHROMYCIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 15

See all 15 trials

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
17-hydroxyprogesterone Caproate vs Castor Oil Injections: Number of Participants With Achievement of 34 Weeks Gestation	0 of 10	0 of 11	21	NCT01050647	Trial comparisons
17-hydroxyprogesterone Caproate vs Castor Oil Injections: Number of Participants With Neonatal Grade III - IV Intraventricular Hemorrhage	1 of 10	2 of 11	21	NCT01050647	Trial comparisons
17-hydroxyprogesterone Caproate vs Castor Oil Injections: Number of Participants With Neonatal Necrotizing Enterocolitis	2 of 10	1 of 11	21	NCT01050647	Trial comparisons
17-hydroxyprogesterone Caproate vs Castor Oil Injections: Number of Participants With Neonatal Respiratory Distress Syndrome	7 of 10	10 of 11	21	NCT01050647	Trial comparisons
17-hydroxyprogesterone Caproate vs Castor Oil Injections: deaths from any cause	0 of 10	0 of 11	21	NCT01050647	Trial comparisons
17-hydroxyprogesterone Caproate vs Castor Oil Injections: serious adverse events	0 of 10	0 of 11	21	NCT01050647	Trial comparisons

Papers from its trials7

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36791845	RESULT	1	PubMed
28710882	RESULT	1	PubMed
26441216	RESULT	1	PubMed
36746334	DERIVED	1	PubMed
36143388	DERIVED	1	PubMed
35947046	DERIVED	3	PubMed
34496799	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0012511

GET https://conductscience.org/api/diseases/v1/MONDO_0012511/drugs?page=2

API reference For AI assistants